A combination mRNA cancer vaccine from BioNTech and Regeneron may be one step closer to actualization based on initial Phase 2 results unveiled Tuesday. The mRNA-based vaccine, BNT111, in combination ...

BioNTech SE is advancing its oncology strategy with investigational therapies BNT327/PM8002 and mRNA cancer immunotherapy candidates to establish a new immuno-oncology backbone targeting a variety of ...

MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the ...

Initiate BioNTech at Sell with $55–$70 fair value, citing 32% downside as cash burn and pipeline risks persist. Click to see ...

MAINZ, Germany, March 11, 2024 – BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American ...

As BioNTech works to establish a production footprint for mRNA vaccines in Africa, two EU groups have offered financial backing to the company's efforts. The European Commission pledged a 35 million ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...

The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values CureVac at around $1.25 billion. Once complete, CureVac will be wholly absorbed ...